United Therapeutics Corp- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 United Therapeutics Corp 公司

United Therapeutics Corporation 是一家制藥公司。該公司營銷和銷售用於治療肺動脈高壓 (PAH) 的商業療法：Tyvaso DPI（曲前列尼爾）吸入粉劑（Tyvaso DPI）；Tyvaso（曲前列尼爾）吸入溶液（霧化 Tyvaso），包括 Tyvaso 吸入系統；Remodulin（曲前列尼爾）注射液（Remodulin）；Orenitram（曲前列尼爾）緩釋片（Orenitram）；和 Adcirca（他達拉非）片劑（Adcirca）。Tyvaso DPI 和霧化 Tyvaso 還獲准用於治療與間質性肺病 (PH-ILD) 相關的肺動脈高壓。該公司還營銷和銷售用於治療高風險神經母細胞瘤的腫瘤產品 Unituxin（dinutuximab）注射液（Unituxin）和用於 Remodulin 的 Remunity 泵（Remunity）。 Tyvaso DPI 是一種藥械組合產品，融合了 MannKind 的 Afrezza（人胰島素）吸入粉中使用的乾粉配方技術和 Dreamboat 吸入裝置技術。

公司簡介

公司代碼UTHR

公司名稱United Therapeutics Corp

上市日期Jun 17, 1999

成立日期1996

CEODr. Martine A. Rothblatt

員工數量1305

證券類型Ordinary Share

年結日Jun 17

公司地址1000 Spring St

城市SILVER SPRING

上市交易所NASDAQ Global Select Consolidated

國家United States of America

郵編20910

電話13016089292

網址https://www.unither.com/

公司代碼UTHR

上市日期Jun 17, 1999

成立日期1996

公司高階主管

名稱

名稱/職務

職務

持股

持股變動

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

-0.06%

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

19.38K

+11.27%

Prof. Nilda Mesa, J.D.

Independent Director

4.88K

-11.67%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

Mr. Christopher Patusky, J.D.

Lead Independent Vice Chairman of the Board

2.00K

-0.20%

Gov. Thomas G. (Tommy) Thompson, J.D.

Independent Director

--

Mr. Christopher A. Causey

Independent Director

--

Mr. James C. Edgemond

Chief Financial Officer, Treasurer

--

名稱

名稱/職務

職務

持股

持股變動

Dr. Martine A. Rothblatt

Chairman of the Board, Chief Executive Officer

666.42K

-0.06%

Mr. Paul A. Mahon, J.D.

Executive Vice President, General Counsel, Corporate Secretary

36.78K

--

Mr. Richard A. Giltner

Independent Director

19.38K

+11.27%

Prof. Nilda Mesa, J.D.

Independent Director

4.88K

-11.67%

The Hon. Dr. Louis W. Sullivan, M.D.

Independent Director

3.20K

--

Mr. Michael Benkowitz

President, Chief Operating Officer

2.65K

+2.76%

收入明細

單位: USD更新時間: 7月6日週日

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

暫無數據

地區USD

名稱

營收

佔比

United States

749.60M

94.36%

Rest of World

44.80M

5.64%

業務

地區

暫無數據

股東統計

更新時間: 5月16日週五

持股股東

股東類型

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

9.93%

The Vanguard Group, Inc.

9.84%

Avoro Capital Advisors LLC

5.93%

State Street Global Advisors (US)

4.95%

Renaissance Technologies LLC

4.67%

Other

64.69%

持股股東

佔比

BlackRock Institutional Trust Company, N.A.

9.93%

The Vanguard Group, Inc.

9.84%

Avoro Capital Advisors LLC

5.93%

State Street Global Advisors (US)

4.95%

Renaissance Technologies LLC

4.67%

Other

64.69%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

48.91%

Investment Advisor

36.17%

Hedge Fund

7.48%

Pension Fund

4.28%

Individual Investor

1.75%

Research Firm

1.52%

Bank and Trust

1.46%

Sovereign Wealth Fund

1.23%

Insurance Company

0.12%

機構持股

更新時間: 7月1日週二

報告期間

機構數

持股數

持股佔比

持股變動

2025Q2

1315

46.61M

103.33%

-1.16M

2025Q1

1369

46.67M

103.49%

-1.81M

2024Q4

1344

46.07M

102.60%

-3.00M

2024Q3

1278

45.38M

101.97%

-7.63M

2024Q2

1219

48.02M

108.26%

-2.92M

2024Q1

1151

47.12M

106.59%

-2.41M

2023Q4

1127

46.52M

99.01%

-2.26M

2023Q3

1094

46.35M

98.80%

-3.96M

2023Q2

1068

46.82M

99.96%

-3.45M

2023Q1

1055

47.11M

101.08%

-1.09M

股東持股明細

名稱

持股數

佔比

持股變動

變動比例

公告日期

BlackRock Institutional Trust Company, N.A.

4.48M

9.93%

+12.87K

+0.29%

Mar 31, 2025

The Vanguard Group, Inc.

4.44M

9.84%

+15.26K

+0.34%

Mar 31, 2025

Avoro Capital Advisors LLC

2.67M

5.93%

-85.30K

-3.09%

Mar 31, 2025

State Street Global Advisors (US)

2.23M

4.95%

+30.71K

+1.40%

Mar 31, 2025

Renaissance Technologies LLC

2.11M

4.67%

+17.60K

+0.84%

Mar 31, 2025

Wellington Management Company, LLP

2.03M

4.49%

-437.48K

-17.76%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.22M

2.71%

+85.70K

+7.53%

Mar 31, 2025

Fidelity Management & Research Company LLC

1.03M

2.29%

-283.67K

-21.55%

Mar 31, 2025

AQR Capital Management, LLC

908.45K

2.01%

-67.00K

-6.87%

Mar 31, 2025

LSV Asset Management

902.32K

2%

-6.40K

-0.70%

Mar 31, 2025

持股ETF

更新時間: 7月6日週日

機構名稱

佔比

Invesco Biotechnology & Genome ETF

4.75%

First Trust NASDAQ Pharmaceuticals ETF

4.03%

Franklin Genomic Advancements ETF

3.58%

First Trust NYSE Arca Biotechnology Index Fund

3.56%

Formidable Fortress ETF

3.1%

Inspire Faithward Mid Cap Momentum ETF

2.83%

Invesco Pharmaceuticals ETF

2.66%

SPDR S&P Biotech ETF

2.62%

ERShares Entrepreneurs ETF

2.41%

Alger Russell Innovation ETF

2.18%

Invesco Biotechnology & Genome ETF

佔比4.75%

First Trust NASDAQ Pharmaceuticals ETF

佔比4.03%

Franklin Genomic Advancements ETF

佔比3.58%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.56%

Formidable Fortress ETF

佔比3.1%

Inspire Faithward Mid Cap Momentum ETF

佔比2.83%

Invesco Pharmaceuticals ETF

佔比2.66%

SPDR S&P Biotech ETF

佔比2.62%

ERShares Entrepreneurs ETF

佔比2.41%

Alger Russell Innovation ETF

佔比2.18%

分紅派息

近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股

公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

United Therapeutics Corp

295.520USD

United Therapeutics Corp

295.520

概覽

公司

財務